Imperial College London
Portrait Picture

ProfessorIanAdcock

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Cell & Molecular Biology
 
 
 
//

Contact

 

+44 (0)20 7594 7840ian.adcock Website

 
 
//

Location

 

304Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hashemian:2021:10.1016/j.pulmoe.2020.10.017,
author = {Hashemian, SM and Shafigh, N and Afzal, G and Jamaati, H and Tabarsi, P and Marjani, M and Malekmohammad, M and Mortazavi, SM and Khoundabi, B and Mansouri, D and Moniri, A and Hajifathali, A and Roshandel, E and Mortaz, E and Adcock, IM},
doi = {10.1016/j.pulmoe.2020.10.017},
journal = {Pulmonology},
pages = {486--492},
title = {Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)},
url = {http://dx.doi.org/10.1016/j.pulmoe.2020.10.017},
volume = {27},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: In December 2019, pneumonia associated with a novel coronavirus (COVID-19) was reported in Wuhan, China. Acute respiratory distress syndrome (ARDS) is the most frequently observed complication in COVID-19 patients with high mortality rates. OBJECTIVE OF STUDY: To observe the clinical effect of plasmapheresis on excessive inflammatory reaction and immune features in patients with severe COVID-19 at risk of ARDS. MATERIALS AND METHODS: In this single-center study, we included 15 confirmed cases of COVID-19 at Masih Daneshvari Hospital, in March 2020 in Tehran, Iran. COVID-19 cases were confirmed by RT-PCR and CT imaging according to WHO guidelines. Plasmapheresis was performed to alleviate cytokine-induced ARDS. The improvement in oxygen delivery (PaO2/FiO2), total number of T cells, liver enzymes, acute reaction proteins, TNF-α and IL-6 levels were evaluated. RESULTS: Inflammatory cytokine levels (TNF-α, IL-6), and acute phase reaction proteins including ferritin and CRP were high before plasmapheresis. After plasmapheresis, the levels of PaO2/FiO2, acute phase reactants, inflammatory mediators, liver enzymes and bilirubin were significantly reduced within a week (p<0.05). In contrast, although the number of T helper cells decreased immediately after plasmapheresis, they rose to above baseline levels after 1 week. Nine out of fifteen patients on non-invasive positive-pressure ventilation (NIPPV) survived whilst the six patients undergoing invasive mechanical ventilation (IMV) died. CONCLUSION: Our data suggests that plasmapheresis improves systemic cytokine and immune responses in patients with severe COVID-19 who do not undergo IMV. Further controlled studies are required to explore the efficacy of plasmapheresis treatment in patients with COVID-19.
AU  - Hashemian,SM
AU  - Shafigh,N
AU  - Afzal,G
AU  - Jamaati,H
AU  - Tabarsi,P
AU  - Marjani,M
AU  - Malekmohammad,M
AU  - Mortazavi,SM
AU  - Khoundabi,B
AU  - Mansouri,D
AU  - Moniri,A
AU  - Hajifathali,A
AU  - Roshandel,E
AU  - Mortaz,E
AU  - Adcock,IM
DO  - 10.1016/j.pulmoe.2020.10.017
EP  - 492
PY  - 2021///
SN  - 2531-0437
SP  - 486
TI  - Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)
T2  - Pulmonology
UR  - http://dx.doi.org/10.1016/j.pulmoe.2020.10.017
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33358260
UR  - https://www.sciencedirect.com/science/article/pii/S2531043720302543?via%3Dihub
UR  - http://hdl.handle.net/10044/1/85199
VL  - 27
ER  -
Download